Disposition and excretion of 6-methoxy-2-naphthylacetic acid, the active metabolite of nabumetone in horses

American Journal of Veterinary Research

Volumn 57, Issue 4, 1996, Pages 517-521

  Soma, L R ^a   Uboh, C E ^b   Rudy, J A ^b   Smith, M S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WEST CHESTER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHOXY 2 NAPHTHYLACETIC ACID; DRUG METABOLITE; NABUMETONE;

ANIMAL EXPERIMENT; ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; HORSE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BUTANONES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; FEMALE; HALF-LIFE; HORSES; INTESTINAL ABSORPTION; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; MOLECULAR STRUCTURE; NAPHTHALENEACETIC ACIDS;

EID: 0029936672     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Dandona P, Jeremy JY Nonsteroidal anti-inflammatory drug therapy and gastric side effects. Does nabumetone provide a solution? Drugs 1990;40(Suppl 5).16-24.
2. Jeremy JY, Mikhailidis DP, Barradas MA, et al. The effect of nabumetone and its principal active metabolite on in vitro human gastric mucosal prostanoid synthesis and platelet function. Br J Rheumatol 1990;29:116-119
3. Jeremy JY, Thompson CS, Mikhailidis DP, et al. Effect of the anti-inflammatory pro-drug, nabumetone and its principal active metabolite on rat gastric mucosal, aortic and platelet eicosanoid synthesis, in vitro and ex vivo Prostaglandins Leukot Essent Fatty Acids 1990;41:195-199
4. Blower PR The unique pharmacologic profile of nabumetone J Rheumatol 1992;Suppl 36 13-29.
5. Haddock RE, Jeffery DJ, Lloyd JA, et al. Metabolism of nabumetone (BRL 14777) by various species including man Xenobiotica 1984,14:327-337
6. Melarange R, Gentry C, O'Connell C, et al. Anti-inflammatory and gastrointestinal effects of nabumetone or its active metabolite, 6-methoxy-2-naphthylacetic acid (6MNA) Comparative studies with indomethacin. Dig Dis Sci 1992;37:1847-1852.
7. Lussier A, LeDel E. Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone. Am J Med 1987;83(Suppl 4B):15-18.
8. Roth SH Endoscopy-controlled study of the safety of nabumetone compared with naproxen in arthritis therapy. Am J Med 1987;83(Suppl 4B)25-30.
9. Greb WH, von Schrader HW, Cerlek S, et al. Endoscopic studies of nabumetone in patients with rheumatoid arthritis. A comparative endoscopic and histologic evaluation. Am J Med 1987, 83(Suppl 4B):19-24.
10. Eversmeyer W, Poland M, DeLapp RE, et al. Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993, 95(Suppl 2A).10S-18S
11. Roth SH, Tindall EA, Jain AK, et al A control study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa. Arch Intern Med 1993;153: 2565-2571.
12. Melarange R, Rashbrook LC. Comparison of the effects of nabumetone with indomethacin on rat gastric mucosal 6-keto-PGF1 alpha production and on bile salt-induced changes in gastric mucosal function. J Pharm Pharmacol 1987;39:717-720.
13. Splangler RS Gastrointestinal damage demonstrated with nabumetone or etodolac in preclinical studies Am J Med 1993; 95(Suppl 2A).35S-39S.
14. Friedel HA, Todd PA. Nabumetone. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in rheumatic diseases. Drugs 1988;35.504-524
15. Poiley JE Nabumetone versus naproxen in the treatment of osteoarthritis. A six-month trial. Am J Med 1987;83(Suppl 4B): 82-85
16. Appelrouth DJ, Baim S, Chang RW, et al. Comparison of the safety and efficacy of nabumetone and aspirin in the treatment of osteoarthritis in adults. Am J Med 1987;83(Suppl 4B):78-81.
17. Hazleman BL, Thomas PP. Single-blind comparative study of nabumetone (Relafen) versus naproxen in the treatment of rheumatoid arthritis. Am J Med 1987;83(Suppl 4B):60-64
18. Helfgott SM Nabumetone: a clinical appraisal. Semin Arthritis Rheum 1994;23:341-346.
19. McMahon FG, Vargas R, Ryan JR, et al. Nabumetone kinetics in the young and old. Am J Med 1987,83(Suppl 4B):92-95
20. Mangan FR, Flack JD, Jackson D. Preclinical overview of nabumetone. Pharmacology, bioavailability, metabolism, and toxicology Am J Med 1987;83(Suppl 4B):6-10.
21. Daigneault EA, Ferslew KE, Stanton P Bioequivalence study of nabumetone tablet versus suspension. Am J Med 1987; 83(Suppl 4B):11-14.
22. Kendall MJ, Chellingsworth MC, Jubb R, et al. A pharmacokinetic study of the active metabolite of nabumetone in young healthy subjects and older arthritis patients Eur J Clin Pharmacol 1989,36:299-305
23. Slattery JT, Levey G. Determination of naproxen and its desmethyl metabolite in human plasma or serum by high performance liquid chromatography. Clin Biochem 1979;12:100-103
24. Soma LR, Uboh CE, Rudy J, et al. Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. Am J Vet Res 1995;56:1025-1080.
25. Boston RC, Greif PC, Berman M. Conversational SAAM - an interactive program for kinetic analysis of biological systems Comput Methods Programs Biomed 1981;13:111-119.
26. Berman M Compartmental analysis in kinetics. In: Stacy RW, Waxman B, eds Computers in biomedical research II. New York: Academic Press Inc, 1965;186-193.
27. Berman M, Weiss MF. SAAM manual (simulation, analysis and modeling). Publication No. NIH 78-180. Washington, DC, US Department of Health, Education, and Welfare, 1978;111-114.
28. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcell Dekker Inc, 1982,149-153,445-449.
29. Torre D, Sampietro C, Maggiolo F Blood and tissue fluid levels of a new non-steroidal anti-inflammatory preparation of nabumetone J Intern Med Res 1987;15 368-373.
30. Hyneck ML. An overview of the clinical pharmacokinetics of nabumetone. J Rheumatol 1992,Suppl 36:20-24.
31. Soma LR, Behrend E, Rudy J, et al. Disposition and excretion of flunixin meglumine in horses. Am J Vet Res 1988;49:1894-1898.
32. Getting EL, Lees P, Taylor JB Pharmacokinetics of phenylbutazone and its metabolites in the horse. Equine Vet J 1981;13: 152-157.
33. Kaneo Y, Kai A, Kiryu S, et al. Protein binding of nonsteroidal anti-inflammatory agents Yakugaku Zasshi 1976;96:1412-1416
34. Soma LR, Gallis DE, Davis WL, et al. Phenylbutazone kinetics and metabolite concentrations in the horse after five days of administration. Am J Vet Res 1983,44:2104-2109.